Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling
RESUMO
Hepatitis C virus (HCV) infection remains a threat to global public health. Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virologic response in about 50% of patients. New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies. Mathematical modeling has played an important role in studying HCV kinetics. Using models, one can evaluate the effectiveness of new treatment agents, estimate important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy. Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how mathematical models have helped to improve our understanding of HCV infection and treatment.
-
Chatterjee Anushree, Smith Patrick F., Perelson Alan S., Hepatitis C Viral Kinetics, Clinics in Liver Disease, 17, 1, 2013. Crossref
-
Amaku Marcos, Coutinho Francisco Antonio Bezerra, Chaib Eleazar, Massad Eduardo, The Impact of Hepatitis A Virus Infection on Hepatitis C Virus Infection: A Competitive Exclusion Hypothesis, Bulletin of Mathematical Biology, 75, 1, 2013. Crossref
-
Halfon Philippe, Locarnini Stephen, Hepatitis C virus resistance to protease inhibitors, Journal of Hepatology, 55, 1, 2011. Crossref
-
Rong Libin, Perelson Alan S., Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents, Mathematical Biosciences, 245, 1, 2013. Crossref
-
Meanwell Nicholas A., D'Andrea Stanley V., Cianci Christopher W., Dicker Ira B., Yeung Kap-Sun, Belema Makonen, Krystal Mark, Antiviral Drug Discovery, in Drug Discovery, 2013. Crossref
-
Fujino Tatsuya, Nakamuta Makoto, Aoyagi Yoko, Kohjima Motoyuki, Satoh Takeaki, Fukuda Mika, Ishibashi Hiromi, Yatsuhashi Hiroshi, Enjoji Munechika, Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin, Medical Science Monitor, 17, 12, 2011. Crossref
-
Rebbani Khadija, Ezzikouri Sayeh, Marchio Agnès, Ababou Mostafa, Kitab Bouchra, Dejean Anne, Kandil Mostafa, Pineau Pascal, Benjelloun Soumaya, Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population, Infection, Genetics and Evolution, 26, 2014. Crossref
-
Reynolds K S, Clinical Pharmacology and Viral Infections, Clinical Pharmacology & Therapeutics, 88, 5, 2010. Crossref
-
Dahari Harel, Guedj Jeremie, Perelson Alan S., Layden Thomas J., Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B, Current Hepatitis Reports, 10, 3, 2011. Crossref
-
Butt A. A., Kanwal F., Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients, Clinical Infectious Diseases, 54, 1, 2012. Crossref
-
Halfon Philippe, Sarrazin Christoph, Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?, Liver International, 32, 2012. Crossref
-
Rong Libin, Guedj Jeremie, Dahari Harel, Coffield Daniel J., Levi Micha, Smith Patrick, Perelson Alan S., Asquith Becca, Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model, PLoS Computational Biology, 9, 3, 2013. Crossref
-
Shi Ruiqing, Cui Yunting, Global analysis of a mathematical model for Hepatitis C virus transmissions, Virus Research, 217, 2016. Crossref
-
Coburn Glen A., Fisch Danielle N., Moorji Sameer M., de Muys Jean-Marc, Murga Jose D., Paul Dorothy, Provoncha Kathleen P., Rotshteyn Yakov, Han Amy Q., Qian Dapeng, Maddon Paul J., Olson William C., Banfield Bruce W., Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture, PLoS ONE, 7, 4, 2012. Crossref
-
Padmanabhan Pranesh, Dixit Narendra M., Regoes Roland Robert, Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry, PLoS Computational Biology, 7, 12, 2011. Crossref
-
Padmanabhan Pranesh, Dixit Narendra M., Castiglione Filippo, Viral Kinetics Suggests a Reconciliation of the Disparate Observations of the Modulation of Claudin-1 Expression on Cells Exposed to Hepatitis C Virus, PLoS ONE, 7, 4, 2012. Crossref
-
Krishnan Sheeja M., Dixit Narendra M., Antia Rustom, Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy, PLoS Computational Biology, 7, 2, 2011. Crossref
-
Cox Jonathan A., Hiscox Julian A., Solomon Tom, Ooi Mong-How, Ng Lisa F. P., Immunopathogenesis and Virus–Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease, Frontiers in Microbiology, 8, 2017. Crossref
-
Castilho Magda Cristina Bernardino, Martins Angélica Nascimento, Horbach Ingrid Siciliano, Perez Renata de Mello, Figueiredo Fatima Aparecida Ferreira, Pinto Paulo de Tarso Aparecida, Nabuco Leticia Cancela, Lima Dirce Bonfim de, Tanuri Amílcar, Porto Luis Cristóvão, Ferreira Júnior Orlando da Costa, Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients, Memórias do Instituto Oswaldo Cruz, 106, 8, 2011. Crossref
-
Goyal Ashish, Ribeiro Ruy, Perelson Alan, The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans, Viruses, 9, 11, 2017. Crossref
-
Ciupe Stanca M., Heffernan Jane M., In-host modeling, Infectious Disease Modelling, 2, 2, 2017. Crossref
-
Liu Xiaoli, Diedrichs-Möhring Maria, Wildner Gerhild, The Role of IFN-alpha in Experimental and Clinical Uveitis, Ocular Immunology and Inflammation, 27, 1, 2019. Crossref
-
Meanwell N.A., Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection, in Comprehensive Medicinal Chemistry III, 2017. Crossref
-
Rocha Rebeca Froes, Del Sarto Juliana Lemos, Marques Rafael Elias, Costa Vivian Vasconcelos, Teixeira Mauro Martins, Host target-based approaches against arboviral diseases, Biological Chemistry, 399, 3, 2018. Crossref
-
Aston Philip, A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications, Viruses, 10, 4, 2018. Crossref
-
EGERMAN ROBERT S., New Antiviral Agents for Treatment of Hepatitis C, Clinical Obstetrics & Gynecology, 62, 4, 2019. Crossref
-
Dickow Julia, Francois Sandra, Kaiserling Rouven-Luca, Malyshkina Anna, Drexler Ingo, Westendorf Astrid Maria, Lang Karl Sebastian, Santiago Mario L., Dittmer Ulf, Sutter Kathrin, Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses, Frontiers in Immunology, 10, 2019. Crossref
-
Veenhuis Rebecca T., Clements Janice E., Gama Lucio, HIV Eradication Strategies: Implications for the Central Nervous System, Current HIV/AIDS Reports, 16, 1, 2019. Crossref
-
Meanwell Nicholas A., Rajamani Ramkumar, Scola Paul M., Sun Li-Qiang, The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032), in HCV: The Journey from Discovery to a Cure, 31, 2019. Crossref
-
Meanwell Nicholas A., Belema Makonen, The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex, in HCV: The Journey from Discovery to a Cure, 32, 2019. Crossref
-
Vlazaki Myrto, Huber John, Restif Olivier, Integrating mathematical models with experimental data to investigate the within-host dynamics of bacterial infections, Pathogens and Disease, 77, 8, 2019. Crossref
-
Fernández-García Raquel, Prada María, Bolás-Fernández Francisco, Ballesteros M. Paloma, Serrano Dolores R., Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing, Pharmaceutical Research, 37, 7, 2020. Crossref
-
Asher Samir, McLornan Donal P., Harrison Claire N., Current and future therapies for myelofibrosis, Blood Reviews, 42, 2020. Crossref
-
da Silva Rafaela Pires, Gonçalves João Ismael Budelon, Zanin Rafael Fernandes, Schuch Felipe Barreto, de Souza Ana Paula Duarte, Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis, Frontiers in Immunology, 12, 2021. Crossref
-
Adekunle Ayooluwatomiwa Deborah, Harp Kathi L., Al-Abdali Zaynab G., Critchfield Agatha S., Barnhart Sheila, Winter Kathleen T., Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State, Infectious Disease Reports, 14, 1, 2021. Crossref
-
Belema Makonen, Lopez Omar D., Bender John A., Romine Jeffrey L., St. Laurent Denis R., Langley David R., Lemm Julie A., O’Boyle Donald R., Sun Jin-Hua, Wang Chunfu, Fridell Robert A., Meanwell Nicholas A., Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors, Journal of Medicinal Chemistry, 57, 5, 2014. Crossref
-
Kienes Ioannis, Weidl Tanja, Mirza Nora, Chamaillard Mathias, Kufer Thomas A., Role of NLRs in the Regulation of Type I Interferon Signaling, Host Defense and Tolerance to Inflammation, International Journal of Molecular Sciences, 22, 3, 2021. Crossref
-
Meanwell Nicholas A., 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph, Journal of Medicinal Chemistry, 59, 16, 2016. Crossref
-
Ali Liaqat, Idrees Muhammad, Ali Muhammad, Hussain Abrar, Rehman Irshad Ur, Ali Amjad, Iqbal Syed Abbas, Kamel Eyad Hassan, Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines, BMC Research Notes, 7, 1, 2014. Crossref
-
Belema Makonen, Meanwell Nicholas A., Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect, Journal of Medicinal Chemistry, 57, 12, 2014. Crossref
-
Afonin Kirill A., Dobrovolskaia Marina A., Church George, Bathe Mark, Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology, ACS Nano, 14, 8, 2020. Crossref
-
St. Laurent Denis R., Serrano-Wu Michael H., Belema Makonen, Ding Min, Fang Hua, Gao Min, Goodrich Jason T., Krause Rudolph G., Lemm Julie A., Liu Mengping, Lopez Omar D., Nguyen Van N., Nower Peter T., O’Boyle Donald R., Pearce Bradley C., Romine Jeffrey L., Valera Lourdes, Sun Jin-Hua, Wang Ying-Kai, Yang Fukang, Yang Xuejie, Meanwell Nicholas A., Snyder Lawrence B., HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity, Journal of Medicinal Chemistry, 57, 5, 2014. Crossref
-
Kumar Anil, Taghi Khani Adeleh, Swaminathan Srividya, Type I interferons: One stone to concurrently kill two birds, viral infections and cancers, Current Research in Virological Science, 2, 2021. Crossref
-
Yasseen Abdool S., Kwong Jeffrey C., Feld Jordan J., Janjua Naveed Z., Greenaway Christina, Lapointe‐Shaw Lauren, Sherman Morris, Mazzulli Tony, Kustra Rafal, MacDonald Liane, Sander Beate, Crowcroft Natasha S., Viral hepatitis C cascade of care: A population‐level comparison of immigrant and long‐term residents, Liver International, 41, 8, 2021. Crossref
-
Lawitz Eric, Rodriguez-Torres Maribel, Denning Jill M., Albanis Efsevia, Cornpropst Melanie, Berrey Michelle M., Symonds William T., Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection, Antimicrobial Agents and Chemotherapy, 57, 3, 2013. Crossref
-
Denning Jill, Cornpropst Melanie, Flach Stephen D., Berrey Michelle M., Symonds William T., Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects, Antimicrobial Agents and Chemotherapy, 57, 3, 2013. Crossref
-
Talemi Soheil Rastgou, Bartenschlager Marie, Schmid Bianca, Ruggieri Alessia, Bartenschlager Ralf, Höfer Thomas, Dengue virus is sensitive to inhibition prior to productive replication, Cell Reports, 37, 2, 2021. Crossref
-
Rabiu Abubakar Abdullahi, Ahmad Rahnuma, Rowaiye Adekunle Babajide, Rahman Sayeeda, Iskandar Katia, Dutta Siddhartha, Oli Angus Nnamdi, Dhingra Sameer, Tor Maryam Abba, Etando Ayukafangha, Kumar Santosh, Irfan Mohammed, Gowere Marshall, Chowdhury Kona, Akter Farhana, Jahan Dilshad, Schellack Natalie, Haque Mainul, Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm, Life, 12, 4, 2022. Crossref
-
Schmitz Yasmin, Schwerdtfeger Mara, Westmeier Jaana, Littwitz-Salomon Elisabeth, Alt Mira, Brochhagen Leonie, Krawczyk Adalbert, Sutter Kathrin, Superior antiviral activity of IFNβ in genital HSV-1 infection, Frontiers in Cellular and Infection Microbiology, 12, 2022. Crossref
-
Saeed Huma, Cano Edison J., Khan Mohammad Qasim, Yetmar Zachary A., Smith Byron, Rizza Stacey A., Badley Andrew D., Mahmood Maryam, Leise Michael D., Cummins Nathan W., Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era, Life, 12, 11, 2022. Crossref